Syndax Pharmaceuticals Inc Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2015 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Syndax Pharmaceuticals Inc quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2015 to Q4 2023.
  • Syndax Pharmaceuticals Inc Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $206M, a 54.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $206M +$72.9M +54.8% Dec 31, 2023 10-K 2024-02-27
Q4 2022 $133M +$35.9M +37% Dec 31, 2022 10-K 2024-02-27
Q4 2021 $97.2M -$4.78M -4.69% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $102M +$17.5M +20.7% Dec 31, 2020 10-K 2022-03-01
Q4 2019 $84.4M +$12.8M +17.8% Dec 31, 2019 10-K 2021-03-12
Q4 2018 $71.7M +$17.2M +31.6% Dec 31, 2018 10-K 2020-03-05
Q4 2017 $54.4M -$5.88M -9.74% Dec 31, 2017 10-K 2019-03-07
Q4 2016 $60.3M +$13M +27.4% Dec 31, 2016 10-K 2018-03-08
Q4 2015 $47.4M Dec 31, 2015 10-K 2017-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.